drugset
drugset / Trial / NCT01151540

A Long Term Extension Study of E2080 in Lennox-Gastaut Patients

NCT01151540 ↗

Phase 3 Completed 54 enrolled Eisai Inc.
NaSingle-groupOpen-labelTreatment

Summary

To investigate the safety of long term administration of E2080 in the patients with Lennox-Gastaut syndrome who completed the E2080-J081-304 Study.

Timeline

Start
2010-11
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Rufinamide Small molecule 45 mg/kg Oral

Indications

Lennox-Gastaut syndrome